Quick Answer
The 12 most predictive longevity biomarkers are VO2 max, fasting insulin, HOMA-IR, hs-CRP, heart rate variability, grip strength, ApoB, liver enzymes (ALT and GGT), vitamin D, homocysteine, uric acid, and fasting triglycerides. Most require only a standard blood draw plus a wearable device. None require expensive genetic tests, and all respond meaningfully to lifestyle intervention.
Standard medical check-ups are designed to catch disease once it has arrived. They are not designed to prevent it, and they are certainly not designed to tell you how fast your body is ageing. A fasting glucose of 98 mg/dL is labelled normal. A fasting insulin of 14 uIU/mL goes unremarked. An hs-CRP of 1.8 mg/L falls within reference range. Yet each of these values, taken together, may describe someone a decade ahead of their age on every metabolic clock we have.
The science of longevity biomarkers has matured considerably over the past two decades. We now have large prospective cohort studies, randomised trials, and Mendelian randomisation analyses that allow us to assign predictive weight to specific measurements. The picture that emerges is consistent: a small panel of inexpensive, accessible markers carries far more prognostic information than chronological age alone.
This article covers twelve biomarkers chosen specifically for their predictive validity: each has been linked to all-cause mortality, healthspan, or biological ageing rate in peer-reviewed literature with replication across multiple populations. For each marker, we cover what it measures, why it matters for longevity, what an optimal target looks like, and how to get it tested. For broader context on what optimal laboratory ranges mean versus standard reference ranges, see our guide to optimal blood test ranges.
It is worth stating clearly what this article does not cover. Epigenetic clocks such as the Horvath clock or DunedinPACE are a separate and genuinely exciting technology, but they belong to a different class of measurement. The markers below are obtainable today from any GP, sports medicine clinic, or direct-to-consumer lab service. They do not require cutting-edge molecular analysis. They require only the decision to look.
Why Predictive Biomarkers Outperform Age as a Risk Measure
Chronological age is a proxy for the accumulated damage that time inflicts on biological systems. It is a useful proxy at the population level: a 70-year-old has, on average, more oxidative damage, greater mitochondrial dysfunction, and higher inflammatory tone than a 30-year-old. But the variance around that average is enormous. Two 55-year-olds sitting in the same waiting room may have biological ages fifteen years apart, and their mortality risk differs accordingly.
Predictive biomarkers are valuable precisely because they capture that variance. They measure physiological processes, not elapsed time. A VO2 max in the top quartile for your age reflects mitochondrial density, cardiac output, and vascular elasticity that no birthday can grant you. A fasting insulin below 5 uIU/mL reflects decades of metabolic discipline. These measurements tell you where you are on the ageing curve, not just how long you have been alive.
The hallmarks of ageing identified by Lopez-Otin and colleagues describe the underlying mechanisms: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. The biomarkers below are, in most cases, downstream readouts of one or more of these mechanisms. Measuring them gives you a window into processes that are otherwise invisible until they produce symptoms.
The 12 Longevity Biomarkers
1. VO2 Max (Cardiorespiratory Fitness)
What it measures: The maximum volume of oxygen your body can consume per kilogram of bodyweight per minute during maximal exertion. It reflects the integrated capacity of your heart, lungs, blood, and skeletal muscle mitochondria to extract and utilise oxygen.
Why it predicts longevity: No single biomarker has a stronger association with all-cause mortality. Mandsager et al. (JAMA Network Open, 2018) analysed 122,007 patients and found that individuals with low cardiorespiratory fitness had a mortality hazard 5.04 times higher than those in the elite fitness category, exceeding the risk attributable to smoking, hypertension, or diabetes. Crucially, this relationship was linear: every step up the fitness ladder reduced mortality, with no ceiling effect. You can read more in our dedicated VO2 max guide.
Optimal target: Age-appropriate top quartile. For a 40-year-old male, this means above approximately 48 mL/kg/min; for a 40-year-old female, above approximately 42 mL/kg/min.
How to test: Formal VO2 max testing at a sports medicine clinic or exercise physiology lab using a metabolic cart during a treadmill or cycle ergometer protocol. Wearables (Garmin, Apple Watch, Polar) provide estimated values via submaximal heart rate modelling, accurate to within approximately 5% in most studies.
2. Fasting Insulin and HOMA-IR
What it measures: Fasting insulin reflects the basal secretory demand on the pancreas. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a derived calculation: fasting insulin (uIU/mL) multiplied by fasting glucose (mmol/L) divided by 22.5. Both detect insulin resistance before glucose dysregulation becomes apparent.
Why it predicts longevity: Joseph Kraft's 1975 analysis of 14,384 insulin assays revealed that 75% of individuals with normal fasting glucose demonstrated abnormal insulin secretion patterns during oral glucose tolerance testing, indicating pre-diabetic physiology invisible to standard screening. Insulin resistance accelerates virtually every hallmark of ageing through hyperinsulinaemia-driven mTOR activation, which suppresses autophagy and promotes cellular senescence.
Optimal target: Fasting insulin below 5 uIU/mL; HOMA-IR below 1.0. Standard laboratory reference ranges extend to 25 uIU/mL, which is diagnostically permissive but metabolically far from optimal.
How to test: Standard blood draw after an overnight fast of at least 10 hours. Fasting insulin is not included in standard panels and must be specifically requested. Calculate HOMA-IR using the formula above.
3. hs-CRP (High-Sensitivity C-Reactive Protein)
What it measures: An acute-phase protein produced by the liver in response to interleukin-6 and other cytokines. The high-sensitivity assay detects concentrations well below those relevant to acute infection or trauma, capturing chronic low-grade systemic inflammation.
Why it predicts longevity: The JUPITER trial (Ridker et al., New England Journal of Medicine, 2008) randomised 17,802 individuals with LDL-C below 130 mg/dL but hs-CRP above 2.0 mg/L. Despite their ostensibly acceptable lipid profiles, these patients had significantly elevated cardiovascular event rates. Rosuvastatin lowered hs-CRP and reduced events by 44%, establishing elevated hs-CRP as an independent cardiovascular risk factor. For detailed coverage of systemic inflammation markers including interleukin-6, see our dedicated guide.
Optimal target: Below 0.5 mg/L. Values between 1.0 and 3.0 mg/L indicate moderate cardiovascular risk; above 3.0 mg/L indicates high risk by American Heart Association criteria, assuming no concurrent acute illness.
How to test: Standard blood draw. Specify hs-CRP rather than standard CRP, as the sensitivity ranges differ substantially. Avoid testing during any acute illness, as even a minor upper respiratory infection will transiently elevate values.
4. Heart Rate Variability (HRV)
What it measures: The beat-to-beat variation in the interval between successive heartbeats, primarily driven by the balance between sympathetic and parasympathetic branches of the autonomic nervous system. RMSSD (root mean square of successive differences) is the most clinically relevant time-domain metric for longevity purposes.
Why it predicts longevity: Tsuji et al. (Circulation, 1994) conducted a four-year follow-up of 2,501 participants in the Framingham Heart Study and found that lower HRV predicted all-cause mortality independently of other risk factors including age, diabetes, and existing cardiovascular disease. HRV declines approximately 3 milliseconds per decade of adult life under average conditions, but elite masters athletes can maintain the HRV of individuals twenty years younger. Our complete HRV guide covers the physiology and training implications in detail.
Optimal target: RMSSD above 50 ms for adults under 50; above 40 ms for adults aged 50 to 65. Individual baselines matter more than population averages: consistent downward trends on a wearable over weeks are more actionable than single readings.
How to test: Oura Ring, Garmin, Apple Watch, and Polar devices all measure overnight HRV. Dedicated chest strap monitors with apps such as HRV4Training provide morning measurements correlated with laboratory-grade ECG recordings.
5. Grip Strength
What it measures: Isometric hand grip force generated against a calibrated dynamometer. It serves as a proxy for total-body skeletal muscle mass, neuromuscular function, and the integrity of the motor system from cortex to peripheral nerve to muscle fibre.
Why it predicts longevity: Ling et al. (BMJ, 2010) followed 555 men and women aged 65 and over for 25 years in the Hertfordshire Cohort Study. Men with grip strength below 26 kg had a 2.5 times higher all-cause mortality than those in the highest grip strength tertile. The relationship held after adjustment for socioeconomic status, physical activity, and chronic disease at baseline. Grip strength captures sarcopenia, the age-related loss of muscle mass that underpins frailty, fall risk, and metabolic deterioration.
Optimal target: Above 40 kg for men; above 28 kg for women, measured as the mean of three attempts on the dominant hand.
How to test: A calibrated Jamar or equivalent hydraulic hand dynamometer. Units cost under 50 dollars for consumer versions. Many physiotherapy practices and sports medicine clinics perform formal assessments.
6. ApoB (Apolipoprotein B)
What it measures: Each atherogenic lipoprotein particle, whether LDL, VLDL, IDL, or Lp(a), carries exactly one ApoB molecule on its surface. ApoB therefore counts the total number of atherogenic particles in circulation, as opposed to LDL-C, which measures the cholesterol mass carried by LDL particles only.
Why it predicts longevity: Sniderman et al. (JAMA Internal Medicine, 2019) demonstrated that ApoB is superior to LDL-C for cardiovascular risk stratification, particularly in individuals with metabolic syndrome or insulin resistance, who often have elevated particle counts despite unremarkable LDL-C. A patient with small, dense LDL particles can have an LDL-C of 110 mg/dL but an ApoB of 130 mg/dL, indicating far greater atherogenic burden than the cholesterol number suggests. Reducing ApoB is now considered the primary therapeutic target in lipid management by multiple cardiology guidelines.
Optimal target: Below 80 mg/dL for longevity purposes; below 60 mg/dL for individuals with established cardiovascular disease or diabetes.
How to test: Standard blood draw; ApoB must be specifically requested as it is not included in routine lipid panels.
7. ALT and GGT (Liver Enzymes)
What they measure: ALT (alanine aminotransferase) is released from hepatocytes under conditions of cellular stress or damage, serving as a sensitive marker of hepatic inflammation. GGT (gamma-glutamyl transferase) reflects hepatic oxidative stress and is particularly sensitive to alcohol intake and early fatty liver infiltration.
Why they predict longevity: Non-alcoholic fatty liver disease affects approximately 25% of the global adult population and substantially elevates cardiovascular mortality. Targher et al. (Lancet Diabetes and Endocrinology, 2010) documented that individuals with NAFLD have more than double the cardiovascular mortality of age-matched controls without hepatic steatosis. Elevated liver enzymes within standard reference range remain a useful early warning signal, particularly when the metabolic health picture is already compromised by high fasting insulin or triglycerides.
Optimal target: Functional targets are stricter than standard laboratory ranges. ALT below 19 IU/L for men and below 15 IU/L for women; GGT below 20 IU/L regardless of sex.
How to test: Included in standard comprehensive metabolic panels. Avoid alcohol for 72 hours before testing and do not test following intense exercise, which transiently elevates AST and ALT.
8. Telomere Length
What it measures: The length of the repetitive DNA sequences capping chromosome ends, measured from blood leukocytes via quantitative PCR or flow-FISH. Telomeres shorten with each cell division and with oxidative stress.
Why it predicts longevity: Elizabeth Blackburn, whose work on telomere biology earned the 2009 Nobel Prize in Physiology or Medicine, demonstrated that critically short telomeres trigger cellular senescence, one of the primary drivers of age-related tissue dysfunction. Population-level studies consistently associate shorter telomere length with age-related disease burden. For a deeper dive into the mechanisms, our article on telomeres and telomerase covers the biology comprehensively.
Important caveat: Individual variation in telomere length is substantial, and the clinical utility of a single measurement at one point in time is limited. Telomere length is most useful as a population-level research tool and as a relative comparison within an individual tracked over years.
How to test: TeloYears (consumer), SpectraCell Telomere Test, or Life Length (clinical-grade flow-FISH). Costs range from approximately $100 to $400.
9. 25-OH Vitamin D
What it measures: 25-hydroxyvitamin D, the stable circulating storage form of vitamin D, reflects the sum of dietary intake, supplemental intake, and cutaneous synthesis from UVB exposure.
Why it predicts longevity: Ginde et al. analysed NHANES III data (Archives of Internal Medicine, 2009) covering 13,331 adults and found that individuals with 25-OH vitamin D below 30 ng/mL had a 26% higher all-cause mortality compared to those above 50 ng/mL, with the relationship strongest for cardiovascular and cancer mortality. Vitamin D receptors are expressed in virtually every nucleated cell in the body, and vitamin D functions as a transcription factor regulating over 1,000 genes involved in immune function, cell proliferation, and inflammatory signalling.
Optimal target: Between 50 and 80 ng/mL (125 to 200 nmol/L). Standard sufficiency thresholds set at 20 to 30 ng/mL are based on bone health alone and do not reflect optimal levels for broader physiological function.
How to test: Standard blood draw; usually included in comprehensive panels. Testing twice per year (late summer and late winter) captures seasonal variation.
10. Homocysteine
What it measures: Homocysteine is a sulfur-containing amino acid produced as an intermediate in methionine metabolism. Its plasma concentration rises when B vitamin cofactors, particularly B6, folate (B9), and B12, are insufficient to clear it through transsulphuration and remethylation pathways.
Why it predicts longevity: Clarke et al. (BMJ, 2002) conducted a prospective meta-analysis of 30 studies involving 5,073 cases of ischaemic heart disease and 1,113 cases of stroke. Each 5 micromole per litre increase in total plasma homocysteine was associated with a 33% higher risk of coronary artery disease and a 59% higher stroke risk, independent of other cardiovascular risk factors. Homocysteine damages endothelial cells directly, promotes oxidative stress, and accelerates arterial stiffening, mechanisms relevant to both cardiovascular and neurodegenerative ageing.
Optimal target: Below 8 micromoles per litre. Standard laboratory upper limits of 15 umol/L identify frank hyperhomocysteinaemia but miss the elevated cardiovascular risk that begins below 10 umol/L.
How to test: Standard fasted blood draw. Must be specifically requested. Specimens must be processed promptly as homocysteine rises in unprocessed blood at room temperature.
11. Serum Uric Acid
What it measures: The end product of purine metabolism in humans, who lack the enzyme uricase that allows most other mammals to break uric acid down further. Serum uric acid reflects dietary purine load, fructose intake (which uniquely drives uric acid production via ATP depletion), and renal excretion capacity.
Why it predicts longevity: Beyond gout, emerging research positions uric acid as a driver of metabolic syndrome and hypertension at levels well below those causing joint disease. Feig et al. (New England Journal of Medicine, 2008) demonstrated in a randomised trial that lowering uric acid in adolescents with hypertension normalised blood pressure in 87% of participants, compared to 38% receiving placebo. Uric acid impairs endothelial nitric oxide production, promotes hepatic fat accumulation, and activates the NLRP3 inflammasome, linking it to systemic inflammation as well as cardiovascular risk.
Optimal target: Below 5.5 mg/dL. Standard upper limits of 7.0 mg/dL identify gout risk but not the metabolic and cardiovascular risk that accumulates at intermediate values.
How to test: Included in standard comprehensive metabolic panels. Avoid foods high in purines (organ meats, shellfish) and fructose-containing beverages for 24 hours before testing.
12. Fasting Triglycerides
What it measures: Triglycerides are the primary storage form of dietary fat and the principal product of hepatic de novo lipogenesis, the process by which excess carbohydrate is converted to fat. Fasting triglycerides therefore reflect both dietary fat load and carbohydrate-driven hepatic fat production.
Why it predicts longevity: Austin et al. (Circulation, 1998) analysed data from 26 prospective studies and found that triglycerides above 150 mg/dL were associated with a doubling of cardiovascular disease risk, independent of HDL-C. Elevated fasting triglycerides are also strongly predictive of insulin resistance: the triglyceride-to-HDL ratio (above 2.0 in conventional units) is frequently used as a surrogate for HOMA-IR in research settings because it correlates so closely with insulin resistance measured directly.
Optimal target: Below 80 mg/dL for true metabolic health. Standard upper limits of 150 mg/dL identify hypertriglyceridaemia but not the elevated metabolic risk that begins around 100 mg/dL. The connection to NAD+ metabolism is also worth noting: high triglycerides correlate with impaired mitochondrial efficiency and reduced NAD+ availability, which accelerates cellular ageing.
How to test: Included in standard lipid panels. A minimum 10-hour fast is required; even small amounts of food, juice, or cream in coffee will substantially elevate results.
Putting the Panel Together: What a Comprehensive Assessment Looks Like
No single marker tells the full story. The power of this panel lies in its composite picture. A 48-year-old with a VO2 max in the top quartile, fasting insulin of 4 uIU/mL, hs-CRP of 0.3 mg/L, and fasting triglycerides of 65 mg/dL is ageing very differently from someone the same age with a low VO2 max, fasting insulin of 16 uIU/mL, hs-CRP of 2.8 mg/L, and triglycerides of 180 mg/dL, even if both individuals have normal fasting glucose and unremarkable standard lipid panels.
When interpreting results, cluster analysis is more informative than individual values. Elevated fasting insulin, high triglycerides, elevated uric acid, and elevated ALT often appear together as markers of metabolic liver dysfunction driven by excess fructose and refined carbohydrate intake. Elevated hs-CRP, low HRV, and elevated homocysteine may cluster in individuals with chronic psychological stress, poor sleep, and B vitamin deficiency. Understanding these patterns directs intervention more precisely than treating each marker in isolation.
For those who want structured guidance on interpreting these markers in the context of their overall metabolic health, the QuanMed AI platform analyses your results against current literature and generates personalised intervention priorities. The goal is not to pathologise, but to identify the highest-leverage changes available to you before disease manifests.
Practical Considerations: Testing Frequency and Cost
The blood-based markers on this list, including fasting insulin, hs-CRP, ApoB, homocysteine, vitamin D, uric acid, liver enzymes, and triglycerides, can typically be drawn together in a single fasting blood draw. The total cost through direct-to-consumer lab services ranges from approximately $150 to $300 in the United States, depending on the provider. UK residents can request most of these via the NHS if they present a clinical case, or access them privately for similar costs.
VO2 max and grip strength require separate assessments but are inexpensive relative to the information they provide. A VO2 max test at a sports medicine clinic typically costs $150 to $300. A hand dynamometer costs under $50 and lasts indefinitely.
For a baseline assessment, running the complete panel once establishes your starting position. Annual repeats track trajectory. If you are actively intervening on a specific cluster, retesting the relevant markers every three to six months keeps your feedback loop tight enough to be motivating. Telomere length, because of its measurement variability and slow rate of change, is typically only worth repeating every three to five years.
Key Sources
- Mandsager K et al. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Netw Open. 2018;1(6):e183605. -- VO2 max and 5x mortality risk versus low fitness category
- Ridker PM et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008;359(21):2195-2207. -- JUPITER trial establishing hs-CRP as independent cardiovascular risk factor
- Sniderman AD et al. The Causal Exposure to ApoB-Containing Lipoproteins and Cardiovascular Risk. JAMA Intern Med. 2019;179(10):1339-1340. -- ApoB superiority over LDL-C for cardiovascular risk stratification
- Ling CH et al. Handgrip strength and mortality in the oldest old population: the Leiden 85-plus study. CMAJ. 2010;182(5):429-435. -- Grip strength below 26 kg associated with 2.5x higher 25-year mortality in men
- Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341-1350. -- NAFLD more than doubles cardiovascular mortality risk in prospective cohort analysis